Key Insights

Highlights

Success Rate

86% trial completion

Published Results

228 trials with published results (22%)

Research Maturity

683 completed trials (65% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

10.4%

110 terminated out of 1054 trials

Success Rate

86.1%

-0.4% vs benchmark

Late-Stage Pipeline

33%

350 trials in Phase 3/4

Results Transparency

33%

228 of 683 completed with results

Key Signals

228 with results86% success110 terminated

Data Visualizations

Phase Distribution

838Total
Not Applicable (242)
Early P 1 (5)
P 1 (57)
P 2 (184)
P 3 (221)
P 4 (129)

Trial Status

Completed683
Unknown112
Terminated110
Recruiting58
Withdrawn37
Not Yet Recruiting26

Trial Success Rate

86.1%

Benchmark: 86.5%

Based on 683 completed trials

Clinical Trials (1054)

Showing 20 of 20 trials
NCT07577817Early Phase 1RecruitingPrimary

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CTX001 in Healthy Adults.

NCT02048813Phase 3Active Not RecruitingPrimary

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT07636473Not ApplicableNot Yet Recruiting

Personalizing Preterm Neonatal Transfusions With Fetal Hemoglobin-Enriched Cord Blood

NCT06976918Recruiting

Research Platform Myelofibrosis and Anemia

NCT07623161Phase 3Not Yet Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

NCT02741648CompletedPrimary

RBC Irradiation, Anemia and Gut Injury

NCT06012760Not ApplicableRecruitingPrimary

The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion

NCT06318858Not ApplicableCompletedPrimary

Daily and Weekly Iron Supplementation in Infants

NCT06898814Phase 4Recruiting

The Effects of Intravenous Iron on Mobility in Elderly Patients Following Hip Fracture Surgery

NCT00843882Phase 3Active Not RecruitingPrimary

Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia

NCT05800600Phase 2RecruitingPrimary

Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy

NCT07092150Not ApplicableActive Not RecruitingPrimary

Long-term Effectiveness and Implementation of the Meals, Education, and Gardens for In-School Adolescents Program

NCT05699005Phase 1Recruiting

Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO

NCT04455841Phase 1Active Not RecruitingPrimary

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

NCT03700034Not ApplicableActive Not Recruiting

mHealth Integrated Model of Hypertension, Diabetes and Antenatal Care in India and Nepal

NCT05320198Phase 1Recruiting

Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia

NCT07025512Phase 2Withdrawn

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

NCT07569172Not ApplicableNot Yet Recruiting

Improved Child Nutrition and Development Through Social Transfers

NCT05732961Phase 2Active Not Recruiting

Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms

NCT05382065CompletedPrimary

Anemia and Duration of Mechanical Ventilation

Scroll to load more

Research Network

Activity Timeline